share_log

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52

Needham維持對Harmony Biosciences的買入,將目標股價上調至5
Benzinga ·  05/01 05:34

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

尼德姆分析師阿米·法迪亞維持Harmony Biosciences(納斯達克股票代碼:HRMY)的買入並將目標股價從50美元上調至52美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論